Trial · NCT03284957
Results by group391
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 391
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 20 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 150 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 200 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 400 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 600 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part A: Amcenestrant 300 mg BID | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part C: Amcenestrant 200 mg + Palbociclib 125 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part C: Amcenestrant 400 mg + Palbociclib 125 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part F: Amcenestrant 200 mg + Alpelisib 300 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part H: Amcenestrant 200 mg + Everolimus 5 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part H: Amcenestrant 200 mg + Everolimus 10 mg | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part J: Amcenestrant 200 mg + Abemaciclib 100 mg BID | 0 | Participants | ||
| Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs) | Part J: Amcenestrant 200 mg + Abemaciclib 150 mg BID | 0 | Participants | ||
| Part B: Objective Response Rate (ORR) as Determined by Independent Central Review (ICR) | Part B: Amcenestrant 400 mg | 10.9 | 90% Confidence Interval 4.4 to 21.5 | percentage of participants | |
| Parts D, I: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs) | Part D: Amcenestrant 200 mg + Palbociclib 125 mg | TEAEs | 30 | Participants | |
| Parts D, I: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs) | Part I: Amcenestrant 200 mg + Everolimus 10 mg | TEAEs | 1 | Participants | |
| Parts D, I: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs) | Part D: Amcenestrant 200 mg + Palbociclib 125 mg | TESAEs | 8 | Participants | |
| Parts D, I: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs) | Part I: Amcenestrant 200 mg + Everolimus 10 mg | TESAEs | 1 | Participants | |
| Parts A, B, C, F, H, J: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events | Part A: Amcenestrant 20 mg | TEAEs | 3 | Participants | |
| Parts A, B, C, F, H, J: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events | Part A: Amcenestrant 150 mg | TEAEs | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03284957/results